Barinthus Biotherapeutics plc. (BRNS) — Institutional Holders, Q2 2026
15 institutional investment managers reported a BRNS position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $7.8M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
BRNS in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- MORGAN STANLEYAdded · +106,633 sh+$70.4K
- Rangeley CapitalAdded · +25,671 sh+$16.9K
- XTX Topco LtdNew · +14,819 sh+$9.8K
- TWO SIGMA SECURITIESNew · +11,052 sh+$7.3K
- UBS Group AGNew · +1,008 sh+$665.00
Biggest sellers
- RENAISSANCE TECHNOLOGIESTrimmed · -126,000 sh-$83.2K
- GTS SECURITIESSold out · -73,210 sh-$48.3K
- CITADEL ADVISORSTrimmed · -42,242 sh-$27.9K
- GEODE CAPITAL MANAGEMENTSold out · -11,568 sh-$7.6K
BRNS 13F holders ranked 1–15 of 15
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | M&G Plc#1 · 5,197,349 sh | 5,197,349 | $5.2M | 0.03% | 0.0% |
| 2 | SC CHINA HOLDING Ltd#2 · 1,420,473 sh | 1,420,473 | $937.5K | 0.08% | 0.0% |
| 3 | GLR Partners#3 · 1,243,377 sh | 1,243,377 | $820.6K | 0.38% | 0.0% |
| 4 | DC Funds#4 · 642,204 sh | 642,204 | $423.9K | 33.82% | 0.0% |
| 5 | Rangeley Capital#5 · 185,136 sh | 185,136 | $122.2K | 0.11% | +16.1% |
| 6 | Johns Hopkins University#6 · 122,237 sh | 122,237 | $80.7K | <0.01% | 0.0% |
| 7 | MORGAN STANLEY#7 · 108,843 sh | 108,843 | $71.8K | 0.00% | +4825.0% |
| 8 | Baird Financial Group#8 · 105,961 sh | 105,961 | $69.9K | <0.01% | 0.0% |
| 9 | CITADEL ADVISORS#9 · 76,754 sh | 76,754 | $50.7K | 0.00% | -35.5% |
| 10 | HighTower Advisors#10 · 37,450 sh | 37,450 | $24.7K | 0.00% | 0.0% |
| 11 | RENAISSANCE TECHNOLOGIES#11 · 25,000 sh | 25,000 | $16.5K | 0.00% | -83.4% |
| 12 | XTX Topco Ltd#12 · 14,819 sh | 14,819 | $9.8K | <0.01% | New |
| 13 | RHUMBLINE ADVISERS#13 · 11,685 sh | 11,685 | $7.7K | 0.00% | 0.0% |
| 14 | TWO SIGMA SECURITIES#14 · 11,052 sh | 11,052 | $7.3K | <0.01% | New |
| 15 | UBS Group AG#15 · 1,008 sh | 1,008 | $665.00 | 0.00% | New |
Funds that sold out of BRNS in Q2 2026 (2)
Held BRNS at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| GTS SECURITIES73,210 sh | 73,210 | $41.9K |
| GEODE CAPITAL MANAGEMENT11,568 sh | 11,568 | $6.6K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.